Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer
Retrieved on:
Thursday, November 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pfizer, Integra, Chemistry, MTX, Kyowa Kirin, University College Utrecht, Patient, Multimedia, Isoti, FDA, Alliance Manchester Business School, IPO, MBA, University, Partnership, Integra LifeSciences, Fast Track, Organon, Management
Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
Key Points:
- Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
- View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies. - Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
- Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.